We develop highly efficient biopharmaceuticals in plants

We at Greenovation develop next generation therapeutics using our proprietary BryoTechnology platform.

Our core competency is optimization and effective production of highly-efficient glycoproteins for the treatment of orphan diseases.

GMP compliant manufacturing of our products is performed in Greenovation’s state-of-the-art wave-bag bioreactor system operated by our partner BIOMEVA.

Greenovation is a privately owned biopharmaceutical company based in Heilbronn, Germany, that was founded in 1999 by Prof. Dr. Ralf Reski and Prof. Dr. Gunter Neuhaus. Today, Zukunftsfonds Heilbronn and
L-EigenkapitalAgentur (Karlsruhe) are main owners of the Greenovation Biotech GmbH.

 

Greenovation is officially a Friend of Rare Disease Day!

Rare Disease Day is held on the last day of February every year to raise awareness of rare diseases. 28 February 2017 marks the tenth international Rare Disease Day. On and around this day hundreds of patient organizations from countries and regions all over the world will hold awareness-raising activities based on the theme of research.